Health Canada And The Competition Bureau Commit To Information Sharing To Combat False, Misleading Or Deceptive Health Claims

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework...
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperation to assist in implementing their respective mandates as they relate to health products.

Information sharing: Provided they are relevant to each Participants' mandates and jurisdictions, and do not conflict with confidentiality obligations or applicable legislation, Participants commit to:

"1. Share information on complaints or inquiries, within the Participants' respective mandates, related to false, misleading or deceptive health claims;

2. Notify each other with respect to matters of mutual interest and exchange timing and other procedural information related to these matters;

3. Share and respond to requests for information related to the administration and enforcement of each Participant's legislation, strategic priorities, marketplace trends, policy and matters that may be of mutual interest;

4. Participate in knowledge transfer sessions to increase expertise in areas of mutual interest related to the laws the Participants administer and/or enforce, including, where appropriate, information obtained from international bodies related to the mandates of the Participants;

5. Coordinate communications (e.g., news releases and consumer alerts), where appropriate; and

6. Meet at least semi-annually to discuss the items enumerated above and to explore further opportunities for cooperation and coordination."

Participants will only share information provided confidentiality is maintained. They will limit access to information and consult on how to protect interests of any third parties whose information could be disclosed. Participants will not exchange or use information if doing so would contravene any relevant legislation. They may use information provided by the other Participant for a purpose different from that for which the information was initially obtained, provided the different purpose is authorized by law.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More